Month: February 2021

NEWARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) — ShotSpotter, Inc. (NASDAQ: SSTI), a leader in precision policing solutions that enable law enforcement to more effectively respond to, investigate and deter crime, will hold a conference call on Thursday, February 25, 2021 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the fourth quarter and full year ended December 31, 2020. Financial results will be issued in a press release prior to the call.ShotSpotter management will host the presentation, followed by a question-and-answer period.Date: Thursday, February 25, 2021Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)U.S. dial-in: 1-855-327-6838International dial-in: 1-604-235-2082Conference ID: 10013082A live audio webcast of the conference call will be available in listen-only mode simultaneously...

MARIETTA, Ga., Feb. 10, 2021 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 17, 2021 at 3:30 PM Eastern Time.A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website or through the conference site by using the link below.Date: Wednesday, February 17, 2021Time: 3:30 PM ETWebcast: https://wsw.com/webcast/btig3/mdxg/1732752A replay of the webcast will be available for approximately 90 days on the...

– Record date for each Special Meeting of Stockholders is February 5, 2021 –– Upon merger closing, combined company will be renamed Aytu Biopharma, Inc. –ENGLEWOOD, Colo. and GRAND PRAIRIE, Texas, Feb. 10, 2021 (GLOBE NEWSWIRE) — Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that the companies’ respective special meetings of stockholders related to the proposed merger between Aytu and Neos have been set for Thursday, March 18, 2021. Stockholders of record of each company as of February 5, 2021 will be eligible to receive notice of and to vote at their respective...

DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference, which is being held February 24th to 26th.About FT218FT218 is an investigational, once-nightly formulation of sodium oxybate that includes Avadel’s MicroPump™ controlled-release (CR) technology. In December 2020, the Company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for FT218 to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. FT218...

TORONTO, Feb. 10, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (CSE: FTRP, FTRP.WT, OTCQX: FTRPF) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its third fiscal quarter ended December 31, 2020, after market close on Tuesday, February 16, 2021.The Company will conduct a conference call and webcast to review its results the following day, Wednesday, February 17 at 8:00 am ET. To access the call, please dial 1-877-407-9716 or 1-201-493-6779 and provide conference ID 13715986. A live webcast of the conference call can be accessed via the Events and Presentations section of the Field Trip Health Investor Relations website or via the following link: http://public.viavid.com/index.php?id=143376.For those unable to attend...

VANCOUVER, British Columbia, Feb. 10, 2021 (GLOBE NEWSWIRE) — Scottie Resources Corp. (“Scottie” or the “Company”) (TSXV: SCOT) is pleased to report drilling results on the infill and expansionary drilling around the Scottie Gold Mine M-zone including intercepts of 12.6 g/t gold and 4.43 g/t silver over 5.22 metres and 10.7 g/t gold and 5.38 g/t silver over 5.70 metres. The 2020 drill results continue to establish both lateral and vertical expansion and continuity of high-grade gold mineralization in the past-producing mine. The 100% owned Scottie Gold Mine is the flagship project of the Company, is road accessible with excellent existing infrastructure, and is located 40 km north of Stewart, BC, and 20 km north of Ascot’s Premier Mill along the Granduc haul road.CEO, Bradley Rourke commented: “The 2020 drill program at the Scottie...

COPENHAGEN, Denmark, Feb. 10, 2021 (GLOBE NEWSWIRE) — Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the closing of its initial public offering of 3,000,000 American Depositary Shares (“ADSs”) at a public offering price of $10.00 per ADS. The gross proceeds from the offering, before deducting underwriting fees and commissions and other offering expenses, were $30 million. The shares began trading on the Nasdaq Capital Market on February 5, 2021 under the ticker symbol “EVAX”.Oppenheimer & Co. Inc. acted as sole book-running manager of the offering. Ladenburg Thalmann & Co. Inc. acted as lead manager of the offering.Evaxion has granted the underwriters an option for...

THIS ANNOUNCEMENT IS FOR INFORMATION ONLY AND IT IS NOT AN OFFER TO BUY OR SOLICITATION OF OFFERS TO BUY ANY SECURITIES. INFORMATION REGARDING THE OFFER TO THE SHAREHOLDERS OF HANDICARE GROUP AB AS ANNOUNCED IN A SEPARATE PRESS RELEASE IS AVAILABLE ONLY TO SHAREHOLDERS IN CERTAIN PERMITTED JURISDICTIONS.LAVAL, Québec, Feb. 10, 2021 (GLOBE NEWSWIRE) — Savaria Corporation (“Savaria”) (TSX: SIS) one of the global leaders in the accessibility industry, is pleased to announce that further to its press release on January 27, 2021, the offer document relating to its previously announced offer to acquire all of the issued and outstanding shares of Handicare Group AB for a final price of SEK50.00 per share (the “Offer”), has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The acceptance...

CETTE ANNONCE EST UNIQUEMENT POUR INFORMATION ET N’EST PAS UNE OFFRE D’ACHAT NI UNE SOLLICITATION D’OFFRES D’ACHAT DE TITRES. LES INFORMATIONS RELATIVES À L’OFFRE AUX ACTIONNAIRES DE HANDICARE GROUP AB, TEL QU’ANNONCÉ DANS UN COMMUNIQUÉ DE PRESSE SÉPARÉ, SONT DISPONIBLES UNIQUEMENT AUX ACTIONNAIRES DANS CERTAINES JURIDICTIONS AUTORISÉES.LAVAL, Québec, 10 févr. 2021 (GLOBE NEWSWIRE) — Corporation Savaria (« Savaria ») (TSX : SIS) un des chefs de file mondiaux de l’industrie de l’accessibilité, a le plaisir d’annoncer qu’à la suite de son communiqué de presse du 27 janvier 2021, le document d’offre relatif à son offre précédemment annoncée d’acquérir toutes les actions émises et en circulation de Handicare Group AB pour un prix final de 50,00 SEK par action (l’« Offre »), a été approuvée et enregistrée par l’Autorité suédoise de surveillance...

VONORE, Tenn., Feb. 10, 2021 (GLOBE NEWSWIRE) — MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) today announced financial results for its fiscal 2021 second quarter ended January 3, 2021.Highlights:Most profitable second quarter in the Company’s historyNet sales increased to $118.7 million, up 19 percent from $99.6 million in the prior-year periodGross margin expanded by 340 basis points to 24.7%Net income was $12.5 million or $0.66 per diluted share, a 78 percent increase from $0.37 in the prior-year periodDiluted Adjusted Net Income per share, a non-GAAP measure, was $0.75, a 74 percent increase from $0.43 in the prior-year periodAdjusted EBITDA, a non-GAAP measure, grew 57 percent to $21.3 million from $13.6 million in the prior-year periodAdjusted EBITDA margin expanded by 430 basis points to 17.9%Guidance for full-year fiscal...